Brivanib, from Bristol Myers Squibb, is an FGFR and VEGFR inhibitor that has anti-angiogenic effects and that is in clinical trials for endometrial cancer (NCT00888173) (Huynh, 2008). No specific data pertaining to the activity of Brivanib against activated or amplified FGFRs is available, however.
Huynh, H, Ong, HS, Fargnoli, J, Ngo, VC, Tran, E, Thng, CH, Byron, S, Soo, KC, Koong, HN, Chow, P, Chung, A, Pollock, P, Ayers, M
© 2023 Reactome